Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesothelin-targeted CAR-NK cells
- Development stage
- Unknown
- Lead developer
- Guojian Chengnuo Biotechnology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intraperitoneal
01
Overview
Mesothelin-targeted CAR-NK cells are an investigational adoptive cell therapy consisting of natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for mesothelin (MSLN). Mesothelin is a cell surface glycoprotein that is highly expressed in several solid tumors, including epithelial ovarian cancer, mesothelioma, and pancreatic cancer, while maintaining limited expression in normal tissues. By targeting MSLN, these CAR-NK cells are designed to selectively bind to and eliminate tumor cells. NK cells offer potential advantages over CAR-T cells, such as a reduced risk of cytokine release syndrome (CRS) and graft-versus-host disease (GvHD), as well as innate anti-tumor mechanisms. Guojian Chengnuo Biotechnology is currently evaluating this therapy via intraperitoneal injection for the treatment of platinum-resistant epithelial ovarian cancer.
- Other names
- MSLN-targeted CAR-NK cellsmesothelin-directed CAR-NK cells间皮素靶向CAR-NK细胞
02
Targets
Mesothelin
Beyond the preview
Go deeper on mesothelin-targeted CAR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesothelin-targeted CAR-NK cells.